reported a 52-year-old patient who was pathologically diagnosed with low-grade glioma and had a BCR-NTRK2 fusion, with no IDH1/2, EGFR, or BRAF gene mutations and no codeletion of chromosomes 1p and 19q. This evidence concerns the gene IDH1 and central nervous system cancer.